Bone Therapeutics Aktie

0,0030 EUR -0,0027 EUR -47,37 %

08:16:29

FSE

0,0041 EUR -0,0002 EUR -4,65 %

17.02.2025

EBR

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Bei einem anderen Broker handeln Smartphone

Marktkap.1,75 Mio. EUR

Div. Rendite0,00%

WKNA14NHV

ISINBE0974280126

SymbolBNZPF

Bone Therapeutics Aktien News

Sortieren:Datum Meistgelesen

08.01.24GlobeNewswireBioSenic signs a new subscription agreement for a maximum of EUR 1.2M in convertible bonds

08.12.23GlobeNewswireERRATUM: BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease

06.12.23GlobeNewswireBioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease

25.10.23GlobeNewswireBioSenic provides third quarter 2023 Business Update

18.10.23GlobeNewswireBioSenic to draw the final tranches of its present Global Tech Opportunities 15 convertible bonds program and secure runway end of January 2024

17.10.23GlobeNewswireBioSenic S.A. : Transparency notifications received from François Rieger, Véronique Pomi, FA Dièse 3 SAS and Capital Grand Est SAS

05.10.23GlobeNewswireBioSenic S.A. : Information on the total number of voting rights and shares

27.09.23GlobeNewswireBioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD

19.09.23GlobeNewswireBioSenic publishes new evidence of beneficial effects of arsenic trioxide treatment supporting clinical trial for systemic sclerosis

14.09.23GlobeNewswireBioSenic reaches agreement on binding term sheets with main creditors to restructure past financial debts

07.09.23GlobeNewswireBioSenic reports half year 2023 results

01.09.23GlobeNewswireBioSenic S.A. : Information on the total number of voting rights and shares

24.08.23GlobeNewswireBioSenic receives a Chinese patent with broad claims, protecting the combined use of metal ions and arsenic salts to treat a wide range of serious diseases

03.08.23GlobeNewswireBioSenic S.A. : Information on the total number of voting rights and shares

10.07.23GlobeNewswireBioSenic provides further update on negotiations with its main creditors

03.07.23GlobeNewswireBioSenic S.A. : Information on the total number of voting rights and shares

30.06.23GlobeNewswireBioSenic provides financial update

20.06.23GlobeNewswireBioSenic presents data on its new copper-arsenic trioxide combination for immunological disorders at the 25th International Conference on Redox Medicine

19.06.23GlobeNewswireBioSenic puts Phase IIb ALLOB trial on hold

01.06.23GlobeNewswireBioSenic SA : Information on the total number of voting rights and shares

29.05.23GlobeNewswireBioSenic provides update regarding current license agreement with Phebra

24.05.23GlobeNewswireBioSenic and Pluristyx sign term sheet for market availability of ALLOB mesenchymal cells

22.05.23GlobeNewswireBioSenic provides First Quarter 2023 Business Update

17.05.23GlobeNewswireBioSenic reacquires global IP rights and provides update on JTA-004 development

15.05.23GlobeNewswireBioSenic to host Annual General Meeting on June 14 2023

04.05.23GlobeNewswireBioSenic identifies key biomarkers for cGvHD and submits patent to EPO

27.04.23GlobeNewswireBioSenic announces 2022 full year results

18.04.23GlobeNewswireBioSenic receives key European patent from EPO, for further therapeutic development in cancer, infectious and immune diseases

03.04.23GlobeNewswireBioSenic appoints Lieven Huysse, MD, as Chief Medical Officer

31.03.23GlobeNewswireBioSenic provides Financial Update and Financial Calendar 2023

30.03.23GlobeNewswireBioSenic publishes new data on the mechanism of action of arsenic trioxide (ATO)

16.03.23GlobeNewswireBioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected patient population

01.03.23GlobeNewswireBioSenic SA: Information on the total number of voting rights and shares

23.02.23GlobeNewswireBioSenic optimizes statistical analysis for its ongoing ALLOB Phase IIb study for high-risk tibial fractures, requiring fewer patients and completes patient recruitment

21.02.23GlobeNewswireBioSenic receives EUR 1 million from Pregene in accordance with terminated license agreement and expect new negotiations on common revisited grounds

14.02.23GlobeNewswireBioSenic announces initiation of coverage by Portzamparc and Gilbert Dupont

Bone Therapeutics News

Bone Therapeutics News: auf dieser Seite finden Sie alle Bone Therapeutics News und Nachrichten zur Bone Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Bone Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Bone Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.